IL1F10 and hyperlipidemia: In the context of lower IL-38 concentrations in patients with the disease, this is a logical hypothesis and was shown effective in e.g., peripheral blood mononuclear cells (PBMCs) from patients with Sjögren’s syndrome (34) and patients with hyperlipidemia (26).